Logo

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Share this

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Shots:

  • The companies plan to initiate a P-II study assessing selgantolimod + VIR-2218 in treatment-experienced and treatment-naïve people living with HBV. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy
  • The 1EPs of the study will be the proportion of patients achieving a functional cure- defined as an off-therapy loss of HBsAg and HBV DNA from the serum. The study is the first P-II study that combines immunomodulation and Ag suppression approaches in HBV cure research
  • Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the P-II study

 ­ Ref: Gilead | Image: Gilead

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions